System L amino acid transporter inhibitor(BCH)in combination with cisplatin inhibits the proliferation of ovarian cancer SKOV3 cells

Zhao Shan,Yang Xingsheng,Bao Xiangxiang

DOI: https://doi.org/10.13283/j.cnki.xdfckjz.2012.02.017

2012-01-01

Abstract:Objective:To explore the effects of System L amino acid transporter inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid(BCH)alone or in combination with cisplatin on the proliferation of human ovarian cancer SKOV3 cells and the possible molecular mechanism.Methods:human SKOV3 cells were treated with different concentrations of BCH alone or combination with cisplatin,the cell viability was assessed by CCK-8 assay;Western blot analysis was performed to detect the affection of mTOR signal pathway by BCH.Results: BCH alone could significantly inhibit the proliferation of SKOV3 cells in time-and dose-manners.Comparing with administration alone,the cell viability was decreased significantly when BCH was combined with cisplatin(P<0.01),and the effect was more significant when BCH treatment followed cisplatin administration(P<0.05).Western blot analysis showed that BCH could inhibit mTOR signal pathway by decreasing the phosphorylation of mTOR,p70 S6K and 4E-BP1.Conclusion:Both BCH alone and in combination with cisplatin can significantly inhibit the proliferation of human ovarian cancer SKOV3 cells,it shows synergistic effects when BCH treatment followed cisplatin administration.